Refractory multiple myeloma with extramedullary plasmacytoma of the spleen and suspicious teratoma: a rare case report and literature review.
Multiple myeloma
primary extramedullary plasmacytomas
teratoma
Journal
International journal of clinical and experimental pathology
ISSN: 1936-2625
Titre abrégé: Int J Clin Exp Pathol
Pays: United States
ID NLM: 101480565
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
09
2017
accepted:
12
12
2017
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
epublish
Résumé
Multiple myeloma (MM) is a type of malignant disease that is characterized by a clonal proliferation of plasma cells within the bone marrow. Relapsed and refractory multiple myeloma (RRMM) is a subtype of MM that is unreactive to salvage therapy and progresses during treatment or within 60 days of the last therapy in patients who achieved a minimal response before progression of disease. This usually results in a poor prognosis. Extramedullary plasmacytoma (EMP) occurs when MM occasionally develops in tissues other than bones marrow. To the best of our knowledge, case studies of the presence of EMPs in the spleen have rarely been reported. Teratoma is a type of congenital tumor that consists of tissue that arises from pluripotent embryonic cells. Here we report a case of refractory immunoglobulin G (IgG) MM with both splenic plasmacytomas and a suspicious teratoma. To investigate the clinical and treatment features of patients under similar conditions, we also reviewed the available literature supporting the useful information in the pathogenesis, diagnosis and treatment of RRMM with EMP.
Types de publication
Journal Article
Langues
eng
Pagination
455-462Informations de copyright
IJCEP Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
Wiley Interdiscip Rev Dev Biol. 2016 Mar-Apr;5(2):186-209
pubmed: 26698368
Oncol Lett. 2015 Oct;10(4):2337-2340
pubmed: 26622847
Leuk Res. 2009 Oct;33(10):1357-60
pubmed: 19201468
Oncol Lett. 2015 Jan;9(1):219-222
pubmed: 25435962
Med Oncol. 1998 Dec;15(4):286-8
pubmed: 9951695
Eur J Haematol. 2012 May;88(5):446-9
pubmed: 22300348
J Oncol Pharm Pract. 2016 Apr;22(2):289-302
pubmed: 25694345
Nat Rev Clin Oncol. 2015 Jan;12(1):42-54
pubmed: 25421279
J Pathol. 2005 Jan;205(1):92-101
pubmed: 15586381
Hematol Oncol. 2017 Jun;35(2):246-251
pubmed: 27018162
Leukemia. 1994 May;8(5):758-67
pubmed: 8182933
Pan Afr Med J. 2013;14:34
pubmed: 23560117
Br J Cancer. 2011 Nov 22;105(11):1684-92
pubmed: 22045184
Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):333-7
pubmed: 23313067
Histopathology. 2011 May;58(6):896-905
pubmed: 21401705
Leuk Res. 2012 Jan;36(1):e34-6
pubmed: 21993312
Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):149-51
pubmed: 20371450
J Gastrointest Cancer. 2012 Jun;43(2):379-81
pubmed: 20703830
Onco Targets Ther. 2012;5:329-34
pubmed: 23152688
Exp Hematol. 2016 Mar;44(3):161-5.e4
pubmed: 26607597
Int J Hematol. 2007 Jul;86(1):69-71
pubmed: 17675270
Med J Malaysia. 2010 Sep;65(3):227-8
pubmed: 21939175
Ann Hematol. 2012 Mar;91(3):473-4
pubmed: 21647581
Aust Fam Physician. 2013 Oct;42(10):684-8
pubmed: 24130968
Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):227-35
pubmed: 25812994
Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E240-2
pubmed: 26085896
Exp Ther Med. 2013 Oct;6(4):883-886
pubmed: 24137282
Leuk Lymphoma. 2013 Jul;54(7):1459-64
pubmed: 23151071
Case Rep Oncol. 2012 Jan;5(1):119-24
pubmed: 22666199
Int J Hematol. 2012 Jun;95(6):706-10
pubmed: 22467268
Zhonghua Xue Ye Xue Za Zhi. 2015 Jan;36(1):44-8
pubmed: 25641146
J Natl Med Assoc. 1989 Oct;81(10):1095-6, 1099
pubmed: 2681801
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
J Med Case Rep. 2015 Feb 19;9:37
pubmed: 25880694
Case Rep Oncol Med. 2016;2016:2490168
pubmed: 27752376
Anticancer Res. 2015 Apr;35(4):2165-8
pubmed: 25862873
Clin Lymphoma Myeloma. 2007 Mar;7(5):373-5
pubmed: 17562249
Can J Surg. 2005 Feb;48(1):75-6
pubmed: 15757045
Cancer Genet Cytogenet. 2000 Feb;117(1):57-60
pubmed: 10700868
Pharmacotherapy. 2015 Dec;35(12):1173-88
pubmed: 26684557